NASDAQ:THOR

Synthorx Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

$67.99

0.00 (0.00%)

(As of 01/23/2020)

Add

Compare

Today's Range: $67.99
▼
$67.99
50-Day Range: $67.99
▼
$67.99
52-Week Range: $11.05
▼
$71.90

Volume: N/A
Average Volume: 474,507 shs
Market Capitalization: $2.20 billion

P/E Ratio: N/A
Dividend Yield: N/A
Beta: N/A

Receive THOR News and Ratings via Email

Sign-up to receive the latest news and ratings for Synthorx and its competitors with MarketBeat's FREE daily newsletter.

About Synthorx

Synthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California.

OrbiMed Names Two New General Partners - Business Wire
December 7, 2021 | businesswire.com

OrbiMed Names Two New General Partners - StreetInsider.com
December 7, 2021 | streetinsider.com

Medicenna Therapeutics: Treating Cancer With Immunomodulators - Seeking Alpha
November 13, 2021 | seekingalpha.com

Nektar: The Anatomy Of A Shakedown - Seeking Alpha
November 10, 2021 | seekingalpha.com

Onchilles Pharma Appoints Christopher Twitty, Ph.D., Chief Scientific Officer
October 28, 2021 | finance.yahoo.com

Onchilles Pharma Appoints Christopher Twitty, Ph.D., Chief Scientific Officer - StreetInsider.com
October 26, 2021 | streetinsider.com

Joint Pain Injections Market Surpass - US$ 10.3 Bn by 2028 - GlobeNewswire
September 30, 2021 | globenewswire.com

Immuno-Oncology Drugs Global Market Report 2021 - ResearchAndMarkets.com - Business Wire
September 29, 2021 | businesswire.com

Immuno-Oncology Drugs Global Market Report 2021: COVID-19 Growth And Change To 2030
September 24, 2021 | uk.finance.yahoo.com

Nektar And Bristol Myers Squibb Expecting Bempeg Approval - Seeking Alpha
September 18, 2021 | seekingalpha.com

Sanofi (SNY) to Buy Kadmon for $1.9B, Add cGVHD Drug Rezurock - Nasdaq
September 8, 2021 | nasdaq.com

Meet the top young leaders transforming the biotech industry
September 8, 2021 | businessinsider.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Health Care Equipment
Sector: Medical
Current Symbol: NASDAQ:THOR
Previous Symbol
CUSIP: 88517530
CIK: 350907
Web: www.synthorx.com
Phone: 858-750-4700
Fax: N/A
Employees: 48
Year Founded: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.72 per share
Price / Book: 10.12

Profitability

EPS (Most Recent Fiscal Year): ($6.59)
Net Income: $-56.61 million
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -26.09%
Return on Assets: -24.62%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 18.87
Quick Ratio: 18.87

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: 32,338,000
Free Float: N/A
Market Cap: $2.20 billion
Optionable: Not Optionable

Company Calendar

Last Earnings: 11/05/2019
Today: 1/20/2022

MarketRank^™

Overall MarketRank^™

1.52 out of 5 stars

Medical Sector

1083rd out of 1,415 stocks

Pharmaceutical Preparations Industry

524th out of 682 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Synthorx.

4.3 Community Rank

Outperform Votes
Synthorx has received 410 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Synthorx has received 223 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Synthorx has received 64.77% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Synthorx and other stocks. Vote “Outperform” if you believe THOR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe THOR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Synthorx does not currently pay a dividend.
Dividend Growth
Synthorx does not have a long track record of dividend growth.

3.3 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Synthorx insiders have not sold or bought any company stock.
Percentage Held by Insiders
53.20% of the stock of Synthorx is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
66.12% of the stock of Synthorx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Synthorx are expected to decrease in the coming year, from ($1.54) to ($2.18) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Synthorx is -16.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Synthorx is -16.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Synthorx has a P/B Ratio of 10.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Synthorx (NASDAQ:THOR) Frequently Asked Questions

How were Synthorx's earnings last quarter?: Synthorx, Inc. (NASDAQ:THOR) posted its quarterly earnings data on Tuesday, November, 5th. The medical instruments supplier reported ($0.38) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.50) by $0.12.
View Synthorx's earnings history.
Who are Synthorx's key executives?: Synthorx's management team includes the following people:
Dr. Laura K. Shawver, CEO, Pres & Director (Age 62, Pay $606.48k)
Dr. Floyd E. Romesberg, Founder (Age 54, Pay $2.68k)
Dr. Marcos Milla Ph.D., Chief Scientific Officer (Age 57, Pay $457.71k)
Dr. Joseph Leveque, Chief Medical Officer (Age 59, Pay $448.76k)
Mr. Tighe M. Reardon C.F.A., CPA, CPA, Acting Chief Financial Officer (Age 44)
Who are some of Synthorx's key competitors?: Some companies that are related to Synthorx include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), IDEXX Laboratories (IDXX), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), STERIS (STE), Hologic (HOLX), Insulet (PODD) and Teleflex (TFX).
View all of THOR's competitors.
What other stocks do shareholders of Synthorx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Synthorx investors own include Pfizer (PFE), Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), Lululemon Athletica (LULU), Micron Technology (MU) and Novartis (NVS).
When did Synthorx IPO?: (THOR) raised $100 million in an IPO on Friday, December 7th 2018. The company issued 9,100,000 shares at a price of $10.00-$12.00 per share. Jefferies, Leerink Partners and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.
What is Synthorx's stock symbol?: Synthorx trades on the NASDAQ under the ticker symbol "THOR."
What is Synthorx's stock price today?: One share of THOR stock can currently be purchased for approximately $67.99.
How much money does Synthorx make?: Synthorx has a market capitalization of $2.20 billion. The medical instruments supplier earns $-56.61 million in net income (profit) each year or ($6.59) on an earnings per share basis.
How many employees does Synthorx have?: Synthorx employs 48 workers across the globe.
What is Synthorx's official website?: The official website for Synthorx is www.synthorx.com.
Where are Synthorx's headquarters?: Synthorx is headquartered at 11099 North Torrey Pines Road Suite 190, La Jolla CA, 92037.
How can I contact Synthorx?: Synthorx's mailing address is 11099 North Torrey Pines Road Suite 190, La Jolla CA, 92037. The medical instruments supplier can be reached via phone at 858-750-4700 or via email at [email protected].

This page was last updated on 1/20/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms

Synthorx Stock Forecast, Price & News

About Synthorx

Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Company Calendar

MarketRank™

Overall MarketRank™

0.0 Analyst's Opinion

4.3 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

0.0 Dividend Strength

3.3 Company Ownership

0.0 Earnings and Valuation

Synthorx (NASDAQ:THOR) Frequently Asked Questions

How were Synthorx's earnings last quarter?

Who are Synthorx's key executives?

Who are some of Synthorx's key competitors?

What other stocks do shareholders of Synthorx own?

When did Synthorx IPO?

What is Synthorx's stock symbol?

What is Synthorx's stock price today?

How much money does Synthorx make?

How many employees does Synthorx have?

What is Synthorx's official website?

Where are Synthorx's headquarters?

How can I contact Synthorx?

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

MarketRank^™

Overall MarketRank^™